YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Ascendis claims its drug delivery technology can be tailored to reduce dosing frequency or deliver a therapeutic molecule ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The firm continues to like the Ascendis story heading into the U.S ... However, it trimmed its Q4 and Q4 Skytrofa revenue estimates and now models total 2024 Skytrofa revenue of EUR 215M.

In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue estimates of €61 million, with the firm's own forecast being € ...

Novo Nordisk and Ascendis Pharma have partnered to develop therapies for metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist that will initially target type 2 ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of $203.00. Tazeen Ahmad has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

The discount rate applied to these earnings remains unchanged at 10%. In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue ...